InMed Pharmaceuticals Inc. (INM)

NASDAQ: INM · IEX Real-Time Price · USD
0.364
+0.032 (9.64%)
At close: Mar 28, 2024, 3:59 PM
0.368
+0.004 (0.96%)
After-hours: Mar 28, 2024, 7:05 PM EDT

Company Description

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products.

The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products.

The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry.

Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs.

The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa.

It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases.

In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin.

The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014.

InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

InMed Pharmaceuticals Inc.
InMed Pharmaceuticals logo
Country Canada
Industry Biotechnology
Sector Healthcare
Employees 13
CEO Eric A. Adams B.S. Chem., M.I.B.

Contact Details

Address:
Suite 310, 815 W. Hastings Street
Vancouver, A1 V6C 1B4
British Columbia, Canada
Phone (604) 669-7207
Website inmedpharma.com

Stock Details

Ticker Symbol INM
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001728328
CUSIP Number 457637601
ISIN Number CA4576376012
SIC Code 2834

Key Executives

Name Position
Eric A. Adams B.S. Chem., M.I.B. President, Chief Executive Officer and Director
Michael Woudenberg P.Eng. Chief Operating Officer
Alexandra Diane-Janet Mancini M.Sc. Senior Vice President of Clinical and Regulatory Affairs
Dr. Sazzad Hossain M.Sc., Ph.D. Co-Founder
N. Netta Jagpal Chief Financial Officer and Corporate Secretary
Sarah Li CPA, CGA Vice President of Accounting and Controller
Colin Clancy Senior Director of Investor Relations
Jerry P. Griffin Vice President of Sales and Marketing
Dr. Eric Chih-Hsien Hsu Senior Vice President of Preclinical Research and Development
Dr. Shane A. Johnson Ph.D. Senior Vice President and GM of BayMedica

Latest SEC Filings

Date Type Title
Mar 20, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 8-K Current Report
Feb 13, 2024 10-Q Quarterly Report
Feb 9, 2024 8-K Current Report
Jan 19, 2024 8-K Current Report
Jan 16, 2024 8-K Current Report
Jan 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Dec 22, 2023 S-8 Securities to be offered to employees in employee benefit plans
Dec 21, 2023 10-K/A [Amend] Annual report